Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

CA 15-3 (Mucin-1) and Physiological Characteristics of Breast Cancer from Lahore, Pakistan

  • Begum, Mumtaz (Department of Biochemistry, Jinnah Medical College) ;
  • Karim, Sajjad (Center of Excellence in Genomic Medicine Research, King Abdulaziz University) ;
  • Malik, Arif (Institute of Molecular Biology and Biotechnology, University of the Lahore) ;
  • Khurshid, Rukhshan (Department of Biochemistry, Jinnah Medical College) ;
  • Asif, Muhammad (Department of Biotechnology and Informatics, BUITEMS) ;
  • Salim, Asmat (Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi) ;
  • Nagra, Saeed Ahmed (Institute of Chemistry, University of the Punjab) ;
  • Zaheer, Ahmad (National Institute for Biotechnology and Genetic Engineering (NIBGE)) ;
  • Iqbal, Zafar (College of Applied Medical Sciences, King Saud Bin Abdulaziz University of Health Sciences, National Guards Health Affairs) ;
  • Abuzenadah, Adel Mohammed (Center of Excellence in Genomic Medicine Research, King Abdulaziz University) ;
  • Alqahtani, Mohammed Hussain (Center of Excellence in Genomic Medicine Research, King Abdulaziz University) ;
  • Rasool, Mahmood (Center of Excellence in Genomic Medicine Research, King Abdulaziz University)
  • Published : 2012.10.31
Download PDF
⟨ Previous Next ⟩

Abstract

Background: High incidence of breast cancer and its fatal effect has reached an alarming stage across the globe, including the third world countries. Many factors have been reported to be associated with the development of breast cancer but detailed structural and functional information is missing. CA 15-3 is one of the known potential tumor marker of breast cancer; however little is known about structure and functional site of this protein. Present study aims to investigate the functional role of CA 15-3 in breast cancer, especially in development and metastasis. Material and Methods: Hundred female breast cancer patients confirmed by histopathological reports were included in the study. Their physiological characters were recorded in a performa. Enzyme linked immunosorbent assay (ELISA) technique was used to estimate serum CA 15-3 level. Immunohistochemistry was done for estrogen (ER), progesterone (PR) and Her2/neu receptors expression. Results: The study revealed the details of physiological characteristics of female breast cancer. Mean age was $37.72{\pm}5.99$ and $55.05{\pm}7.28$ years and serum CA 15-3 (MUC1) level was $60.47{\pm}8.59$ and $63.17{\pm}4.58$ U/ml in pre and post-menopause respectively, and both groups of women had sedentary life style. Their receptor status especially of progesterone, estrogen and HER-2/neu were positive in 50% of premenopausal women and 65% of postmenopausal women. Conclusion: There are multiple physiological factors promoting breast cancer. High serum CA 15-3 level and hormonal imbalance of ER, PR and Her2/neu appears to be the main cause of breast cancer. It may be possible that the functional sites of these proteins may be altered which may increase the chances of metastasis in breast cancer.

Keywords

References

  1. Ahmed F, Mahmud S, Hatcher J, Khan SM (2006). Breast cancer risk factor knowledge among nurses in teaching hospitals of Karachi, Pakistan: a cross-sectional study. BMC Nur, 5, 6-8. https://doi.org/10.1186/1472-6955-5-6
  2. Ahmed F, Mahmud S, Hatcher J, Khan SM (2006). Breast cancer risk factor knowledge among nurses in teaching hospitals of Karachi, Pakistan: a cross-sectional study. BMC Nur, 5, 6-8. https://doi.org/10.1186/1472-6955-5-6
  3. Bairoch A, Apweiler R (1997). The SWISS-PROT protein sequence data bank and its supplement TrEMBL. Nucleic Acids Res, 25, 31-6. https://doi.org/10.1093/nar/25.1.31
  4. Balducci L, Beghe C, Parker M, Chausmer A (2005). Prognostic evaluation in geriatric oncology: problems and perspectives. Archives of Gerontology and Geriatrics, 3, 31-41.
  5. Barnes BB, Chang Claude J, Flesch Janys D, et al (2009). Cancer risk factors associated with insulin-like growth factor (IGF)-I and IGF-binding protein-3 levels in healthy women: effect modification by menopausal status. Cancer Causes Control, 20, 1985-96. https://doi.org/10.1007/s10552-009-9393-0
  6. Baruch A, Hartmann M, Yoeli M, Adereth Y, et al (1999). The breast cancer-associated MUC1 gene generates both a receptor and its cognate binding protein. Cancer Res, 59, 1552-61.
  7. Baum M, Denton S (1981). Breast cancer: the facts. Oxford University Press, 15-40.
  8. Beenken SW, Grizzle WE, Crowe DR, et al (2001). Molecular biomarkers for breast cancer prognosis: coexpression of c-erbB-2 and p53. Ann Surg, 233, 630-8. https://doi.org/10.1097/00000658-200105000-00006
  9. Cancer Research UK, (2012). UK Breast Cancer Incidence Statistics. Retrieved 11.9.2012, from http://info.cancerresearchuk.org/cancerstats/types/breast/incidence/
  10. Dumitrescu RG (2005). Understanding breast cancer risk-where do we stand in 2005? J Cell Mol Med, 9, 208-21. https://doi.org/10.1111/j.1582-4934.2005.tb00350.x
  11. Fan NJ, Gao CF, Zhao G, Wang XL, Liu QY (2012). Serum peptidome patterns of breast cancer based on magnetic bead separation and mass spectrometry analysis. Diagn Pathol, 20, 45.
  12. Gendler SJ (2001). MUC1, the renaissance molecule. J Mammary Gland Biol Neoplasia, 21, 339-53.
  13. Gierach GL, Ichikawa L, Kerlikowske K, et al (2012). Relationship between mammographic density and breast cancer death in the breast cancer surveillance consortium. J Natl Cancer Inst, 104, 1218-27. https://doi.org/10.1093/jnci/djs327
  14. Hindle WH (1990). Breast disease for gynaecology: epidemiology-risk factors. Appleton and Lange Norwalk, 30.
  15. Howe GR, Freidenrich CM, Jaim M, Miller AB (1991). A cohort study of fat intake and risk of breast cancer. J Natl Cancer Inst, 83, 336-40. https://doi.org/10.1093/jnci/83.5.336
  16. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  17. Jiang XP, Yang DC, Elliot RL, Head JF (2000). Vaccination with a mixed vaccine of autogenous and allogeneic breast cancer cells and tumor associated antigens CA15-3, CEA and CA125-results in immune and clinical responses in breast cancer patients. Cancer Biother. Radiopharm, 15, 495-505. https://doi.org/10.1089/cbr.2000.15.495
  18. Kakugawa Y, Minami Y, Tateno H, Inoue H, Fujiya T (2007). Relation of serum levels of estrogen and dehydroepiandrosterone sulfate to hormone receptor status among postmenopausal women with breast cancer. Breast Cancer, 14, 269-76. https://doi.org/10.2325/jbcs.14.269
  19. Khan A, Newman LA (2004). Diagnosis and management of ductal carcinoma in situ. Curr Treat Options Oncol, 5, 131-44. https://doi.org/10.1007/s11864-004-0045-z
  20. Korde LA, Calzone KA, Zujewski J (2004). Assessing breast cancer risk: genetic factors are not the whole story. Postgrad Med, 116, 19-20.
  21. Kufe DW (2012). MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene. doi: 10.1038/onc.2012.158. [Epub ahead of print].
  22. Liu C, Zhang H, Shuang C, et al (2010). Alternations of ER, PR, HER-2/neu, and P53 protein expression in ductal breast carcinomas and clinical implications. Med Oncol, 27, 747-52. https://doi.org/10.1007/s12032-009-9279-8
  23. Miller AB, Berrino F, Hill M, Riobali PE, Wahramdrof J (1994). Diet in the aetiology of cancer: a review. Eur J Cancer, 30, 207-20. https://doi.org/10.1016/0959-8049(94)90088-4
  24. Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE (2004). Endogenous estrogen, androgen and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst, 96, 1856-8. https://doi.org/10.1093/jnci/djh336
  25. Molina R, Auge JM, Farrus B, et al (2010). Prospective evaluation of carcinoembryonic antigen (CEA) and carbohydrate antigen 15.3 (CA 15.3) in patients with primary locoregional breast cancer. Clin Chem, 56, 1148-57. https://doi.org/10.1373/clinchem.2009.135566
  26. Mukherjee P, Ginardi AR, Tinder TL, Sterner CJ, Gendler SJ (2001). MUC1-specific cytotoxic T lymphocytes eradicate tumors when adoptively transferred in vivo. Clin Cancer Res, 7, 848-55.
  27. Muttlin C (1984). Diet and the epidemiology of breast cancer. Cancer, 53, 605-11. https://doi.org/10.1002/1097-0142(19840201)53:3+<605::AID-CNCR2820531305>3.0.CO;2-0
  28. Norum LF, Nilsson O, Nustad K (2001). Automated immunofluorometric assay for MUC. Tumour Biol, 22, 169-75. https://doi.org/10.1159/000050612
  29. Perkins EA, Small BJ, Balducci L, et al (2007). Individual differences in well-being in older breast cancer survivors. Crit Rev Oncol/Hematol, 62, 74-83 https://doi.org/10.1016/j.critrevonc.2006.11.002
  30. Parry S, Silverman HS, McDermott K, Willis A (2001). Identification of MUC1 proteolytic cleavage sites in vivo, Biochem. Biophys. Res Commun, 283, 715-20. https://doi.org/10.1006/bbrc.2001.4775
  31. Rahn JJ, Chow JW, Horne GJ, et al (2005). MUC1 mediates transendothelial migration in vitro by ligating endothelial cell ICAM-1. Clin Exp Metastasis, 22, 475-83. https://doi.org/10.1007/s10585-005-3098-x
  32. Rakha EA, Boyce RW, Abd D, et al (2005). Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Mod Pathol, 18, 1295-304. https://doi.org/10.1038/modpathol.3800445
  33. Sandri MT, Salvatici M, Botteri E, et al (2012). Prognostic role of CA15.3 in 7942 patients with operable breast cancer. Br Cancer Res Treat, 132, 317-26. https://doi.org/10.1007/s10549-011-1863-x
  34. Sattin RW, Rubin GL, Webster LA, et al (1985). Family history and the risk of breast cancer. Breast Cancer Res, 253, 230-41.
  35. Saxena N, Hartman M, Bhoo-Pathy N, et al (2012). Breast cancer in South East Asia: comparison of presentation and outcome between a middle income and a high income country. W J Surg, 36, 2838-46. https://doi.org/10.1007/s00268-012-1746-2
  36. Segal-Eiras A, Croce MV (1997). Breast cancer associated mucin: a review. Allergol Immunopathol (Madr), 25, 176-81.
  37. Tang Y, Wang L, Zhang P, et al (2010). Detection of circulating anti-mucin 1 (MUC1) antibodies in breast tumor patients by indirect enzyme-linked immunosorbent assay using a recombinant MUC1 protein containing six tandem repeats and expressed in Escherichia coli. Clin Vaccine Immunol, 17, 1903-8. https://doi.org/10.1128/CVI.00142-10
  38. Truant S, Bruyneel E, Gouyer V, et al (2003). Requirement of both mucins and proteoglycans in cell-cell dissociation and invasiveness of colon carcinoma HT-29 cells. Int J Cancer, 104, 683-94. https://doi.org/10.1002/ijc.11011
  39. Tsuda H (1994). Accumulation of gene alterations and progression of breast cancer. Gan To Kagaku Ryoho, 21, 172-7.
  40. VanLith ML, Kohlgraf KG, Sivinski CL, Tempero RM (2002). Hollingsworth MA.MUC1-specific anti-tumor responses: molecular requirements for CD4-mediated responses. Int Immunol, 14, 873-82. https://doi.org/10.1093/intimm/dxf053
  41. Verkooijen HM, Chappuis PO, Rapiti E, et al (2006). Impact of familial risk factors on management and survival of early-onset breast cancer: a population-based study. Bri J Cancer, 94, 231-8. https://doi.org/10.1038/sj.bjc.6602914
  42. Vrieling A, Buck K, Heinz J, et al (2012). Pre-diagnostic alcohol consumption and postmenopausal breast cancer survival: a prospective patient cohort study. Br Cancer Res Treat, 136, 195-207. https://doi.org/10.1007/s10549-012-2230-2
  43. Voet D, Voet JG, Pratt CW (1999). Fundamentals of Biochemistry. John Wiley and Sons, Inc, New York.
  44. Wei X, Xu H, Kufe D (2006). MUC1 oncoprotein stabilizes and activates estrogen receptor alpha. Mol Cell, 21, 295-305. https://doi.org/10.1016/j.molcel.2005.11.030
  45. Zhang HM, Xuan LX, Gao JD, Zhang BN, Zhao P (2009). Clinical characteristics comparison between triple-negative and non-triple-negative breast cancer. Zhonghua Wai Ke Za Zhi, 47, 506-10.

Cited by

  1. Usefulness of Salivary and Serum Auto-antibodies Against Tumor Biomarkers HER2 and MUC1 in Breast Cancer Screening vol.17, pp.1, 2016, https://doi.org/10.7314/APJCP.2016.17.1.335
  2. nanotube arrays vol.8, pp.11, 2016, https://doi.org/10.1039/C5AY02290H
  3. Course of SP-D, YKL-40, CCL18 and CA 15-3 in adult patients hospitalised with community-acquired pneumonia and their association with disease severity and aetiology: A post-hoc analysis vol.13, pp.1, 2018, https://doi.org/10.1371/journal.pone.0190575